|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Long-term use of tumor necrosis factor inhibitors for the treatment of especially eye disease in Behçet syndrome seems to be safe and efficacious.
|
31609785 |
2020 |
|
Behcet Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
When nongranulomatous uveitis (BD and HLA-B27-associated uveitis) was compared with granulomatous uveitis (sarcoidosis and VKH disease), the levels of sCD30 and sTNFRI/TNF-α and sTNFRII/TNF-α ratios were significantly enhanced in granulomatous uveitis.
|
31804623 |
2019 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, novel biotherapy approaches, including interferon-α (IFN-α), tumor necrosis factor-α (TNF-α) antagonists, and other agents that target interleukins and their receptors, have shown promising results in the treatment of patients with refractory BD and have improved the prognosis of BD.
|
30984205 |
2019 |
|
Behcet Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, association of the other IL-23R polymorphisms could not be estimated owing to the lack of studies.<b>Abbreviations</b>: BD: Behcet's disease; SNP: single nucleotide polymorphism; HLA: human leukocyte antigen; IL: interleukin; OR: odds ratio; CI: confidence interval; HWE: Hardy-Weinberg equilibrium; UK: United Kingdom; NOS: Newcastle-Ottawa scale; GWAS: genome-wide association study; TNF-α: tumor necrosis factor-α.
|
31814470 |
2019 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-tumor necrosis factor-α monoclonal antibodies are effective for refractory intestinal Behçet's disease in real-world situations.
|
30872086 |
2019 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, increasing data with the tumor necrosis factor inhibitors suggest that these agents may also be acceptable options for the management of refractory vascular BD in daily practice.
|
29665281 |
2019 |
|
Behcet Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease.
|
31228955 |
2019 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report on the therapeutic use of anti-TNF monoclonal antibodies for BD-associated NVD and NVE in one pediatric patient (subcutaneous adalimumab) and one young man (intravenous infliximab).
|
28700280 |
2019 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF)-blocking agents such as Infliximab, Etanercept, and Adalimumab have been reported to have success in patients with BD.
|
29631062 |
2018 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
MIC-A, TNF-α genes) identified as associated to BD because of their LD with HLA-B*51.
|
30252881 |
2018 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment with 30 µg/ml curcumin also significantly diminishes the protein production of TNFα in BD patients (p < .01) and healthy controls (p < .05) M1 macrophages.
|
29806793 |
2018 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Disease activity levels at the start of treatment predict duration of response to monoclonal TNF antagonists in ocular BD.
|
29671190 |
2018 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
For example, tumor necrosis factor inhibitors are quite successful in the treatment of rheumatoid arthritis (RA), Behçet's disease (BD), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) but not in that of systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's syndrome (SS) and antineutrophil cytoplasmic antibody-associated vasculitis (AAV), conversely, RA shares genetic backgrounds more with SLE, SSc, SS and AAV than BD, AS and PsA.
|
29623390 |
2018 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
To describe the outcome and tolerance in patients treated with anti-TNFα in severe and refractory major vessel disease in Behçet's disease (BD).
|
30125675 |
2018 |
|
Behcet Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study designed to analyze the miR-146a and miR-155 expression in patients with Behcet's disease (BD) and investigated their association with the expression of tumor necrosis factor-alpha (TNF-α) and cytotoxic T lymphocyte associated antigen-4 (CTLA-4) genes.
|
30366049 |
2018 |
|
Behcet Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study was designed to explore the interrelationship between single nucleotide polymorphisms (SNP) of the tumor necrosis factor superfamily (TNFSF) and its respective receptor superfamily (TNFRSF) genes and Behcet's disease (BD) and Vogt-Koyanagi-Harada syndrome (VKH) in Han Chinese.
|
29285231 |
2017 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficacy of tumor necrosis factor-alpha inhibitors, interferon α and anti-interleukin-1 agents was shown in noncontrolled studies of ocular Behçet disease.
|
27662569 |
2017 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
New uncontrolled data suggest beneficial effects of anti-TNFs for refractory extra-ocular complications of BS such as pulmonary artery, gastrointestinal and central nervous system involvement.
|
27791958 |
2017 |
|
Behcet Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Among the cytokines related to innate immunity, the levels of IL-1α, IL-1 β, IL-6, IL-12, IL-15 and TNF-α were statistically higher in BD patients than healthy controls.
|
27939191 |
2017 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings may suggest a signature of IL-6, tumor necrosis factor-α as well as of Th17 response in BD patients due to increased levels of gp130/sIL-6Rb, sTNF-R1, sTNF-R2, IL-26, respectively.
|
28289419 |
2017 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the various immunodysfunctions that are found in BD, patients are increased neutrophil motility and superoxide production, as well as elevated production of tumor necrosis factor (TNF)-α and decreased production of interleukin (IL)-10.
|
28693405 |
2017 |
|
Behcet Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The pathogenesis of BD has not been fully elucidated; however, BD has been considered to be a typical Th1-mediated inflammatory disease, characterized by elevated levels of Th1 cytokines such as IFN-γ, IL-2, and TNF-α.
|
28753995 |
2017 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF-α) participates in the pathophysiology of Behcet's disease (BD) and myelodysplastic syndrome (MDS).
|
29390339 |
2017 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Areas covered: The following article aims to summarize the currently available efficacy and safety data of anti-TNFα agents in BD.
|
28503960 |
2017 |
|
Behcet Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The findings of this study, collectively, indicate that TNF-α -857C-1031C haplotype located in the promoter region of the gene could exert major influence on the susceptibility to BD.
|
27914129 |
2017 |